Italian Multicenter Study on Hepatocellular Carcinoma Immunotherapy Outcomes

146 patients with unresectable hepatocellular carcinoma and cirrhosis were treated with Atezolizumab and Bevacizumab across Italian centers. This retrospective study compares outcomes between multidisciplinary clinics and standard oncology care, analyzing survival, response rates, and treatment duration. Data includes primary outcomes like overall survival and progression-free survival, and secondary metrics such as disease control rate.

Use Cases

• Compare overall survival and progression-free survival between MDTc and standard clinic groups using the 146 patient records.
• Analyze disease control rate and objective response rate to assess treatment efficacy across different care models.
• Investigate the association between treatment duration and liver-related event discontinuation rates.
• Model the impact of inverse probability weighting adjustment on the significance of clinical outcome associations.

Strengths

• Includes data from 146 patients across multiple Italian centers for a multicentre analysis.
• Reports specific clinical metrics including median overall survival of 19.7 vs 13.4 months and progression-free survival of 13.6 vs 7.7 months.
• Provides detailed secondary outcomes like disease control rate (70.1% vs 60.3%) and treatment duration (8 vs 4 months).

Limitations

• Small sample size of 146 patients limits statistical power for subgroup analyses.
• Retrospective study design introduces potential for selection bias and confounding.
• Inverse probability weighting analysis rendered the primary association non-significant, indicating baseline imbalances.

Provenance

Source

figshare admin karger

Collection Method

Multicentre retrospective study

Time Range

null

Freshness

null

Geography

Italy